Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.09.19
Views: 676

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Prof Robert Coleman speaks to ecancer at ESMO 2019 in Barcelona about the VELIA/GOG-3005 trial looking at PARP inhibitor veliparib with frontline chemotherapy and maintenance for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin.

He explains that this is the first trial to asses a PARP inhibitor given with chemotherapy and this has been possible dye to the unique characteristics of veliparib.

Prof Coleman reports that giving the PARP inhibitor with chemotherapy and continued with maintenance therapy benefited women in all cohorts.

Read our news article on this study here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation